Welcome to Viral Genetics, Inc.

Viral Genetics Announces
Licensing Deal With
University of Colorado
and V-Clip Pharmaceuticals, Inc.

Click here for more.

New to Viral Genetics?
View our History and
Product Development Timeline.

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.

Our management team, board and advisors include world-renowned experts in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency.

Viral Genetics Announces Licensing Deal with University of Colorado and V-Clip Pharmaceuticals, Inc. Click here for more.

Viral Genetics Appoints Scientific Development Manager to Focus on Translational Studies. Click here for more.

Viral Genetics Builds African Advisory Team. Viral Genetics, Inc. (OTCBB: VRAL) has retained two senior advisors as part of its African advisory team as the Company continues the development of VGV-1, the Company’s HIV/AIDS product, in Africa. Click here for more.

VGV-1 was originally discovered during the course of studying TNP as a means of detecting HIV infection. When suspended in adjuvant, we found TNP to be capable of more than just HIV detection but actually as a potential treatment for HIV/ AIDS.

VRAL:OB